ES2113213T3 - Derivados de indol como agonistas de tipo 5ht1. - Google Patents

Derivados de indol como agonistas de tipo 5ht1.

Info

Publication number
ES2113213T3
ES2113213T3 ES95934124T ES95934124T ES2113213T3 ES 2113213 T3 ES2113213 T3 ES 2113213T3 ES 95934124 T ES95934124 T ES 95934124T ES 95934124 T ES95934124 T ES 95934124T ES 2113213 T3 ES2113213 T3 ES 2113213T3
Authority
ES
Spain
Prior art keywords
sub
sup
indol
derived
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934124T
Other languages
English (en)
Inventor
Alan Daniel Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2113213T3 publication Critical patent/ES2113213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I), SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES (INCLUYENDO HIDRATOS) DE CUALQUIER ENTIDAD, EN DONDE R{SUP,1} ES (A) R{SUP,2} ES R{SUP,3}R{SUP,4}C(()OH())A; V ES C=O O CH{SUB,2}; W ES O O NR{SUP,5}; R{SUP,3} Y R{SUP,4} SON CADA UNO INDEPENDIENTEMENTE SELECCIONADOS DE H Y ALQUILO C{SUB,1}C{SUB,4}; O, JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN INCORPORADOS, FORMAN UN ANILLO CARBOCICLICO DE 4 O 5 MIEMBROS; R{SUP,5} ES H, BENCILO, ALCANILO C{SUB,1}-C{SUB,5} O SO{SUB,2}(()C{SUB,1}-C{SUB,4}())ALQUILO; A ES ALQUILENO C{SUB,2}C{SUB,3}; M ES 0 O 1; Y N ES 0 O 1; CON LA CONDICIONES DE QUE CUANDO N SEA 1 Y V SEA C=O, ENTONCES W SEA NH, Y DE QUE CUANDO N SEA 1 Y V SEA CH{SUB,2}, ENTONCES W SEA O; SON AGONISTAS TIPO 5-HT1 SELECTIVOS UTILES EN EL TRATAMIENTO DE, ENTRE OTRAS, MIGRAÑA, JAQUECA, HEMICRANEA PAROXISMAL CRONICA Y DOLOR DE CABEZA ASOCIADO A TRASTORNOS VASCULARES.
ES95934124T 1994-10-11 1995-09-29 Derivados de indol como agonistas de tipo 5ht1. Expired - Lifetime ES2113213T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9420503A GB9420503D0 (en) 1994-10-11 1994-10-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2113213T3 true ES2113213T3 (es) 1998-04-16

Family

ID=10762688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95934124T Expired - Lifetime ES2113213T3 (es) 1994-10-11 1995-09-29 Derivados de indol como agonistas de tipo 5ht1.

Country Status (11)

Country Link
US (1) US5770611A (es)
EP (1) EP0785933B1 (es)
JP (1) JP2902484B2 (es)
AT (1) ATE163934T1 (es)
DE (1) DE69501791T2 (es)
DK (1) DK0785933T3 (es)
ES (1) ES2113213T3 (es)
FI (1) FI113863B (es)
GB (1) GB9420503D0 (es)
GR (1) GR3026532T3 (es)
WO (1) WO1996011195A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
HUP0102935A3 (en) 1998-06-03 2002-01-28 Gpi Nil Holdings Inc Wilmingto N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres and pharmaceutical compositions containing them
KR100747106B1 (ko) * 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
WO2011158149A1 (en) 2010-06-18 2011-12-22 Pfizer Inc. 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
CA2124206C (en) * 1991-11-25 2001-02-27 John Eugene Macor Indole derivatives
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
EP0635015B1 (en) * 1992-04-10 1997-01-29 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis

Also Published As

Publication number Publication date
MX9702643A (es) 1997-07-31
JPH09512034A (ja) 1997-12-02
GR3026532T3 (en) 1998-07-31
DE69501791D1 (de) 1998-04-16
WO1996011195A1 (en) 1996-04-18
DE69501791T2 (de) 1998-07-02
JP2902484B2 (ja) 1999-06-07
FI971492A0 (fi) 1997-04-10
ATE163934T1 (de) 1998-03-15
FI971492L (fi) 1997-04-10
DK0785933T3 (da) 1998-05-11
EP0785933B1 (en) 1998-03-11
US5770611A (en) 1998-06-23
GB9420503D0 (en) 1994-11-23
FI113863B (fi) 2004-06-30
EP0785933A1 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
ES2094653T3 (es) Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña.
ES2137562T3 (es) Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina.
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
ES2132093T3 (es) 6- o 7-(imidazolidin-2-ilidenamino)-1,4-benzoxazinas como agentes alfa-adrenergicos.
ES2063830T3 (es) Agentes antitumorales.
ES2113368T3 (es) Antagonistas de serotonina.
UA27467C2 (uk) ПОХІДНІ ІНДОЛУ ЯК 5-НТ<sub>1</sub> АГОНІСТИ ТА ПРОМІЖНІ СПОЛУКИ
AR004493A1 (es) Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen.
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2065133T3 (es) Derivados de piperazina.
CO5630036A2 (es) Nuevos derivados indol con afinidad por el receptor 5-ht6
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
BG96180A (bg) Нови антихистаминови средства,производни на бензимидазолите
DE3268225D1 (de) 9-(2-(3-indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
FI832092A0 (fi) 1-aryloxi-2,3,4,5-tetrahydro-3-bensazepiner, foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel
SE9603283D0 (sv) New compounds
NO880843D0 (no) 3-amino-dihydro-(1)-benzopyraner og benzotiopyraner.
SE8505887L (sv) Indoler
ES2159345T3 (es) Indazolcarboxamidas.
ES2108595B1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
ES2188029T3 (es) Fenil-alquil-imidazoles como antagonistas del receptor h3.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 785933

Country of ref document: ES